Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation

NCT04610892 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04610892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04610892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2020
Completion date
November 8, 2023
Enrollment
423 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

coronary heart disease (chd)